Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05109364 · ClinicalTrials.gov registry record · Phase 2

Terazosin and Parkinson's Disease Extension Study

A Phase 2 study of REM Sleep Behavior Disorder and Symptomatic Parkinson Disease, sponsored by Cedars-Sinai Medical Center.

Active
Registry status
Phase 2
Development phase
15
Enrollment target
1
Study location

NCT05109364: Active Phase 2 study of REM Sleep Behavior Disorder and Symptomatic Parkinson Disease, sponsored by Cedars-Sinai Medical Center.

NCT05109364 is a Phase 2 study of REM Sleep Behavior Disorder and Symptomatic Parkinson Disease that is active but no longer recruiting, run by Cedars-Sinai Medical Center. The registered enrollment target is 15 participants, below the 156-participant average among 11 other REM Sleep Behavior Disorder trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05109364, a Phase 2 study of REM Sleep Behavior Disorder and Symptomatic Parkinson Disease, is active but no longer recruiting, sponsored by Cedars-Sinai Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to investigate the long-term effects of treatment with the selective post-synaptic a1-adrenergic blocker terazosin on serial in a population of subjects with defined pre-motor Parkinson's disease (PD) risks and abnormal imaging exams. Imaging changes will be correlated to the presence and severity of motor and non-motor symptoms of PD, measured by validated clinical scales and cardiac autonomic function tests.

Primary Outcome

123I-MIBG early reuptake will be measured by Heart to Mediastinal ratio (H/M) which will be calculated from the early images after drawing regions of interest (7×7 pixels) over the upper mediastinum and circular ROI around the entire heart. MIBG abnormality cutoff will be set for values of late H/M \<2.2.

Conditions Studied

REM Sleep Behavior Disorder Symptomatic Parkinson Disease Pre-motor Parkinson's Disease

Interventions

  • DRUG Terazosin therapy

Study Locations (1)

California

  • Cedars Sinai Medical Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2022-09-23
Est. Completion 2026-03-10
Phase Phase 2
Cedars-Sinai Medical Center

339 total trials

What the registry record for NCT05109364 still lists

NCT05109364 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 156-participant average among 11 other REM Sleep Behavior Disorder trials with a reported enrollment target (90% lower).

The record links to 3 conditions, with REM Sleep Behavior Disorder appearing as the primary indexed condition, and to 1 intervention - of which Terazosin therapy is the first listed.

NCT05109364 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05109364 about?

NCT05109364 is a clinical study titled "Terazosin and Parkinson's Disease Extension Study". The purpose of this study is to investigate the long-term effects of treatment with the selective post-synaptic a1-adrenergic blocker terazosin on serial in a population of subjects with defined pre-motor Parkinson's disease (PD) risks and abnormal imaging exams. Imaging changes will be correlated t...

What is the current status of trial NCT05109364?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2022-09-23. Estimated completion is 2026-03-10.

What conditions does trial NCT05109364 study?

This clinical trial studies the following conditions: REM Sleep Behavior Disorder, Symptomatic Parkinson Disease, Pre-motor Parkinson's Disease.

What interventions are being tested in trial NCT05109364?

The interventions under investigation include: Terazosin therapy (DRUG).

Who is sponsoring clinical trial NCT05109364?

This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05109364 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for REM Sleep Behavior Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05109364's enrollment target sits among peer trials

15 9th of 11 the lowest of 11 other REM Sleep Behavior Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other REM Sleep Behavior Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05109364, the US trial registry maintained by the National Library of Medicine. NCT05109364 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.